Viewing Study NCT02784158

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:58 PM
Ignite Modification Date: 2026-02-23 @ 3:02 PM
Study NCT ID: NCT02784158
Status: NO_LONGER_AVAILABLE
Last Update Posted: 2018-02-06
First Post: 2016-05-24
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Sponsor: Ariad Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-small Cell Lung Cancer View
None Lung Cancer View
None Advanced Malignancies View
None Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Non-small cell lung cancer View
None Non-small cell lung carcinoma View
None Epithelial lung cancer View
None Squamous cell carcinoma View
None Large cell carcinoma View
None Adenocarcinoma View
None Anaplastic lymphoma kinase (ALK) View
None Carcinoma View
None Advanced Cancers View
None Brigatinib View
None AP26113 View